SNOA - Sonoma Pharmaceuticals rallies after hours on partnership with Gabriel Science

Sonoma Pharmaceuticals (SNOA) +33.7% AH, entered into a non-exclusive distribution agreement with Gabriel Science for the sale of Microcyn Technology products into the dental market and has accepted its first order.Endocyn, a Microcyn Technology product manufactured by Sonoma, is a biocompatible root canal irrigant that does not stain teeth or restorations.."Our proprietary Microcyn technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety. This partnership also furthers Sonoma’s strategy of expanding its offerings of Microcyn-powered products available in the U.S. market.," CEO Amy Trombly commented.

For further details see:

Sonoma Pharmaceuticals rallies after hours on partnership with Gabriel Science